The Gut May Be the Point: Metformin, Citrulline, and the Exercise Question

The Bottom Line For years, one worry has followed metformin into the longevity and performance world: the drug inhibits mitochondrial complex I, exercise depends on mitochondrial adaptation, so maybe metformin mutes the very training signal we are trying to build. A new Nature Metabolism paper complicates that picture in a useful way. It argues that the clinically relevant complex I inhibition from oral metformin happens largely in the lining of the gut, where the drug is concentrated, and not so much in skeletal muscle, where tissue levels are low.

That lowers one concern: the crude "metformin poisons muscle mitochondria" story looks too simple. But it does not clear metformin as exercise-neutral. The same paper points somewhere more interesting. Metformin suppresses intestinal citrulline synthesis, citrulline feeds nitric oxide, and nitric oxide governs the blood-flow side of exercise. The authors themselves raise the possibility that this, not direct muscle inhibition, is how metformin blunts some training adaptations.

My calibrated read: the concern did not disappear. It moved upstream, from muscle mitochondria toward the gut, citrulline, nitric oxide, and vascular perfusion. That is a sharper, more testable question than the one we have been arguing about.

---

Vocabulary that matters

• Mitochondrial complex I: the first big entry point of the cell's energy-production line inside mitochondria. Metformin can slow it down. Where it does so at normal doses is the whole question.
• Intestinal epithelium: the thin cell layer lining the gut. It meets the drug first after a pill, so it sees far higher metformin concentrations than muscle or liver.
• Citrulline: an amino acid made almost entirely by the small intestine. It is the body's main raw material for refilling arginine, which feeds nitric oxide.
• Nitric oxide (NO): a short-lived signal that tells blood vessels to relax, matching blood flow to a working muscle's demand for oxygen and fuel.
• Hormesis: the principle that a controlled stress produces a beneficial adaptation. Exercise is the cleanest human example. The stress is not the benefit. The adaptation is.

---

I came to this paper the way a lot of people did this week: Eric Topol flagged it, and a good conversation formed around it. The study is Sebo and colleagues at Northwestern, in Nature Metabolism, and its title is dry enough to scroll past: "Metformin inhibits mitochondrial complex I in intestinal epithelium to promote glycaemic control."¹ It is not a paper about exercise. But buried in its discussion is a hypothesis that should make anyone in the longevity and performance world stop scrolling. I want to walk through why, and where I think the honest read lands.

This is a research note, not one of my cardiovascular chapters. It sits a little outside the personal story I have been telling. I am writing it because the timing is right and the mechanism is genuinely interesting, and because it previews biology that is tied to the hallmarks of aging, the living chemistry of the blood vessel wall, that the rest of this series is heading toward anyway.

The old concern, and why it was reasonable

Metformin occupies a strange cultural position. In diabetes care it is ordinary, with decades of use behind it. In longevity circles it became something else: a candidate geroprotective drug, a way to nudge nutrient sensing, mitochondrial stress, and maybe aging itself. That is why healthy, already-exercising people started taking an interest in a diabetes medication.

And with that interest came a tension. The simple version of the worry goes like this. Metformin inhibits mitochondrial complex I. Exercise produces its adaptations partly by stressing mitochondria. So perhaps metformin interferes with the stress signal we are trying to create. That concern was never unreasonable. It just may have been pointed at the wrong tissue.

I will say where I stand on the underlying tradeoff, because it frames everything below. Exercise is the higher-confidence longevity intervention without any doubt in my mind. Its outcome data across cardiovascular disease, diabetes prevention, frailty, and mortality are deep and consistent. Metformin's case as a longevity drug in otherwise healthy people is not settled. So if I had to choose between protecting exercise adaptation and chasing a possible metformin longevity signal in a healthy person, I protect the adaptation. That is not an anti-metformin position. It is an evidence-hierarchy position. The real question was never "is metformin bad," but "in whom, for what goal, and at what cost to the adaptations we earn through training?"

What the human exercise data actually show

The concern is not built on nothing. In a 2019 Aging Cell trial, older adults trained aerobically with metformin or placebo. Exercise improved several cardiometabolic markers regardless of treatment. But metformin attenuated the training gains in whole-body insulin sensitivity and VO₂max, and it blocked the exercise-induced increase in skeletal-muscle mitochondrial respiration.² That paper fueled the "metformin blunts exercise" conversation.

The same year, the MASTERS trial tested resistance training in adults 65 and older. The hypothesis going in was that metformin might help muscle by lowering inflammation. The opposite happened: the placebo group gained more lean and thigh muscle mass, and metformin appears to have negatively affected the hypertrophic response.³

A 2026 systematic review and meta-analysis pooled controlled trials across the spectrum of glucose dysregulation. Adding metformin to structured exercise modestly attenuated improvements in peak oxygen uptake and blood pressure, while glycemic and lipid outcomes were not clearly better with the combination.⁴ And a 2026 vascular trial added another layer: in adults at risk for metabolic syndrome, metformin blunted the exercise-training gains in vascular insulin sensitivity at both the large-artery and capillary level. In plain terms, the blood vessels did not adapt to training as well when metformin was on board.⁵

So the signal exists. But here is the part that matters for mechanism: the muscle-mitochondria explanation is not airtight. A secondary analysis of two randomized trials, using direct human muscle biopsies, found that metformin did not significantly affect exercise-induced changes in muscle mitochondrial respiration, oxidative stress, or AMPK activation. The authors wrote, in 2022, that further work was needed to see whether the interaction lived "in other tissues, e.g., the gut."⁶

That sentence reads very differently after this new paper.

What the new paper changes

Sebo and colleagues argue that metformin's glucose-lowering effect depends heavily on complex I inhibition in intestinal epithelial cells, the lining of the gut.¹ That matters because oral metformin does not spread evenly through the body. The gut sees it first and at the highest local concentration. The authors make the muscle point directly, in their own words:

“

A direct inhibitory effect of metformin on muscle mitochondria is unlikely due to the low concentration of metformin in this tissue.

To test the gut's role, they used a clean genetic trick. They engineered intestinal cells to carry an alternative enzyme, NDI1, that lets mitochondria bypass complex I inhibition. When the gut was shielded this way, much of metformin's usual metabolic effect weakened. In their model, the intestine is co-opted into a glucose sink: complex I inhibition pushes gut cells toward pulling in glucose and converting it to lactate, and it raises signals like Lac-Phe and GDF15 that sit in the broader appetite and body-weight conversation.¹

The piece that was most interesting to me here is citrulline. The enzymes that build citrulline live in the mitochondria and, in humans, are expressed almost exclusively in the liver and small intestine. The liver keeps its citrulline for the urea cycle; the gut releases its citrulline into the bloodstream, where it becomes the body's main feedstock for nitric oxide. Critically, those citrulline-making enzymes need mitochondrial ATP, which is exactly what complex I inhibition starves. So when metformin slows the gut's mitochondria, citrulline production falls. The authors confirmed this across human metabolomic data and an obese type 2 diabetes cohort, and showed in mice that the drop tracks specifically to the intestine, not the liver.¹

The proposed mechanism, in one line: not muscle mitochondria directly, but gut metabolism upstream, citrulline downstream, nitric oxide and perfusion in the middle, and exercise adaptation at the end. That last stretch, from citrulline to blunted training, is the authors' hypothesis and not a settled result.

The citrulline pivot and why it caught my eye specifically

Here is the passage that turns a diabetes-mechanism paper into something the performance world should read. In their own discussion, the authors note that circulating citrulline is the primary precursor to nitric oxide, "a potent vasodilator essential for muscle perfusion during exercise." They point out that citrulline rises with exercise in humans and is "the dominant ingredient in many pre-workout supplements because it enhances muscle perfusion and exercise performance." And then they make the link explicit: it is plausible that metformin-induced citrulline depletion, and therefore reduced nitric oxide, underlies the blunted exercise benefits seen with the drug.¹

I want to be precise about authorship of this idea, because attribution is the whole brand here. I raised the citrulline angle in the conversation around the paper before I had actually dug into the full text; the authors raise the same mechanism in their own discussion. That is convergence, not a claim of originality on my part. And honestly, the authors stating it themselves makes it stronger, not weaker.

What I can add is a particular vantage point on that one sentence. I have known citrulline for more than twenty-five years, from two very different worlds. The first was the supplement industry where I not only ran companies but worked in supplement formulation, where citrulline (usually as citrulline malate) is exactly what the authors say it is: the workhorse "pump" ingredient in pre-workout formulas, sold on the promise of better blood flow and a better session. The second, more serious, is the last year and a half I have spent reading the endothelial and nitric-oxide literature, the biology of how the vessel wall actually decides to open or stay shut. Most of the supplement world knows the first frame. Most of the cardiology world knows the second. The interesting thing about this paper is that it sits exactly on the seam between them, and that seam is where I have spent a lot of time.

And I'll be straight about my own stake: I use citrulline myself, in the context of known nitric-oxide-pathway genetics and close blood-pressure tracking. That isn't a recommendation, it's why this one sentence in someone else's diabetes paper isn't abstract for me. The genetics, endothelial health, and workout optimization topics all deserve their own post, and this isn't it. I will be addressing each directly in the weeks to come.

Oral citrulline does raise plasma arginine and augment nitric-oxide-dependent signaling in humans, dose-dependently. In a controlled crossover study it raised arginine more effectively than swallowing arginine itself.¹⁰ What is not established is the step the new paper hypothesizes: that replacing citrulline restores exercise adaptation in someone on metformin. No trial has tested it.

Two good things do not always add

The reason "blunting" is a real category, and not just pharmaceutical paranoia, is that exercise works partly because it is a controlled stress. You generate reactive oxygen species, inflammatory signals, shear stress against the vessel wall. The body reads that stress and adapts: mitochondria, capillaries, endothelium, glucose handling. Blunt the stress and you can blunt the adaptation.

This is not hypothetical. High-dose antioxidant supplementation is the cleanest example. In one well-known human study, vitamin C and E blocked the exercise-induced improvement in insulin sensitivity and prevented some of the body's own antioxidant-defense response.⁷ A separate randomized trial found the same vitamins attenuated markers of mitochondrial biogenesis after endurance training.⁸ Post-workout cold-water immersion tells a similar story. It helps with acute soreness, but repeated use right after lifting attenuated anabolic signaling and long-term strength adaptations.⁹

None of that makes antioxidants or cold exposure "bad." It makes the point that timing, dose, population, and goal decide whether two good things add cleanly or interfere. That is the frame I bring to metformin. The concern is not that the drug is toxic. It is that exercise adaptation is a stress-response program, and metformin is a drug that changes cellular stress biology.

What I would actually want to see tested

The authors go one step further than I would. They write that supplementing citrulline "could be a straightforward and scalable solution" to support exercise adaptation in people on metformin.¹ I would put more daylight between the mechanism and the recommendation. The hypothesis is clean and the rationale is real, but there is no randomized trial testing citrulline against metformin's exercise blunting. Until there is, this is a study design, not a protocol.

The trial nearly writes itself. Take adults beginning a structured exercise program and randomize exercise plus placebo, exercise plus metformin, and exercise plus metformin plus citrulline. Then measure the things that actually answer the question: citrulline, arginine, nitric-oxide metabolites, flow-mediated dilation, microvascular blood flow, VO₂max, blood pressure, hypertrophy, and strength. In people who genuinely need glycemic control, keep the design clinically appropriate. The point is not whether glucose improves. Metformin already does that in the right person. The point is whether the exercise-adaptation cost can be separated from the glucose benefit. That is the real longevity question hiding inside this paper.

One honest caveat about my own toolkit. I usually lean on epigenetic clocks to judge whether something is touching aging biology, and a moment ago I waved them off. That was too quick. Clock data on metformin does exist. It is early, and it does not point cleanly in one direction. A rigorous 40-month study in monkeys reported that metformin decelerated several molecular aging clocks, including roughly a six-year regression in brain aging.¹¹ The human picture is thinner and more mixed. A 2025 study that isolated metformin found no significant change in a glycan-based measure of biological age.¹² A promising animal signal sitting next to an unsettled human one is exactly the kind of gap that earns its own post rather than a throwaway line here, and I will give it one.

Where this is heading

This note is also a doorway. My cardiovascular series is moving away from my personal story and toward the biology of the vessel wall: the endothelium, the inner lining of the artery that is alive and decides, beat by beat, whether to relax, constrict, repair, or inflame. Nitric oxide is the molecule at the center of that decision, and citrulline is one of its raw materials. I have my own reasons to watch that pathway closely, including the genetics of how I personally produce and handle nitric oxide, and a cardiovascular history that makes the question concrete rather than abstract.

I am not unpacking that here. It deserves its own chapters, and they are coming: the endothelium, nitric oxide, and the genetics underneath them. This metformin paper just gave us an early, well-timed look through that door.

What this does and does not change

This paper partially mitigates one specific concern: that standard oral metformin directly inhibits skeletal-muscle mitochondria enough to explain exercise blunting. The authors' own argument, high drug exposure in the gut and low exposure in muscle, makes the simple "poisons muscle mitochondria" story look too crude. That matters, because a lot of the longevity conversation has treated metformin as if it broadly suppressed mitochondrial function everywhere at normal doses.

It does not clear metformin as exercise-neutral. The human signal is still there: blunted VO₂max, blunted hypertrophy, and blunted vascular adaptation in some settings. What changed is the suspected route: less about muscle mitochondria, more about gut metabolism, citrulline depletion, nitric oxide, and perfusion.

And it does not flatten the differences between people. A 68-year-old with poorly controlled type 2 diabetes and high cardiovascular risk is not the same question as a healthy 42-year-old taking metformin because a podcast called it a longevity drug. Different risks, different upside, different evidence thresholds. The mistake is pretending one answer covers all of them.

The Calibrated Claim Audit

Claim	Mechanism strength	Evidence quality	What epi clocks say	My read	What would change my mind
Metformin's glucose effect is substantially gut-mediated.	Strong	Strong mechanistic paper; still evolving clinically	Not the tool here	Meaningfully updates the model	Human isotope/tissue data confirming gut-first dominance
Standard oral metformin directly inhibits muscle mitochondria enough to explain exercise blunting.	Weaker after this paper	Mixed; a human-biopsy analysis is null	Not the tool here	Less central than I thought	Direct human muscle data showing relevant complex I inhibition
Metformin can blunt some exercise adaptations.	Plausible	Moderate; RCTs plus 2026 meta-analysis	Absent	Real, but not universal	Larger trials showing no effect across VO₂max, BP, muscle, vascular
Citrulline could preserve exercise adaptation in metformin users.	Plausible	Hypothesis only; no RCT	Absent	Interesting study design, not a recommendation	An RCT showing restored NO/perfusion and preserved adaptation

Commercial distortion risk: moderate. The studies underneath this question are largely publicly funded. That includes NIH money, European public science, and the new Nature Metabolism paper itself, most with explicit no-conflict declarations. The distortion does not live in the evidence. It lives in the two marketing narratives layered on top, metformin sold as a longevity drug and citrulline sold as a performance supplement. That split is why I hold the citrulline idea at "untested hypothesis" even though the paper's own authors reach a little further.

The Final Signal

• What this paper gets right. It makes the metformin mechanism tissue-specific. The gut, not the muscle, may be the main site of clinically relevant complex I inhibition, which makes the direct muscle-mitochondria fear less convincing.
• What it does not settle. It does not prove metformin is exercise-neutral. The human blunting signal is still there for cardiorespiratory fitness, blood pressure, hypertrophy, and vascular adaptation in some settings.
• What got more interesting. Citrulline. If metformin lowers gut-made citrulline, and citrulline feeds nitric oxide, the exercise interaction may be partly vascular rather than purely mitochondrial, and the authors say so themselves.
• What I am not doing. I am not recommending citrulline with metformin, not giving doses, and not turning a mechanism note into a protocol. I'd hold this more conservatively than the paper does.
• What comes next. Several more stories on my hunt for all the potential causes of going from 0% coronary atherosclerosis at 36 to an 80% RCA blockage at 44, nitric oxide, the endothelium, the genetics underneath them, and then deviating to deep analysis on the interventions the longevity industry says can help and where I personally sit on the matter. This paper was a timely preview of where the series was already going.

---

References

1. Sebo ZL, Chakrabarty RP, Grant RA, et al. Metformin inhibits mitochondrial complex I in intestinal epithelium to promote glycaemic control. Nat Metab. 2026. PMID: 42103929 · doi:10.1038/s42255-026-01530-y
2. Konopka AR, Laurin JL, Schoenberg HM, et al. Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults. Aging Cell. 2019;18(1):e12880. PMID: 30548390
3. Walton RG, Dungan CM, Long DE, et al. Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: a randomized, double-blind, placebo-controlled, multicenter trial: The MASTERS trial. Aging Cell. 2019;18(6):e13039. PMID: 31557380
4. Etayo-Urtasun P, Sáez de Asteasu ML, Izquierdo M. The effects of metformin and exercise training on cardiorespiratory, blood pressure, and metabolic adaptations across the spectrum of glucose dysregulation: a systematic review and meta-analysis. EClinicalMedicine. 2026;95:103915. PMID: 42051241
5. Malin SK, Heiston EM, Battillo DJ, et al. Metformin Blunts Vascular Insulin Sensitivity After Exercise Training in Adults at Risk for Metabolic Syndrome. J Clin Endocrinol Metab. 2026;111(4):e1124-e1135. PMID: 41160096
6. Pilmark NS, Oberholzer L, Halling JF, et al. Skeletal muscle adaptations to exercise are not influenced by metformin treatment in humans: secondary analyses of 2 randomized, clinical trials. Appl Physiol Nutr Metab. 2022;47(3):309-320. PMID: 34784247
7. Ristow M, Zarse K, Oberbach A, et al. Antioxidants prevent health-promoting effects of physical exercise in humans. Proc Natl Acad Sci U S A. 2009;106(21):8665-8670. PMID: 19433800
8. Paulsen G, Cumming KT, Holden G, et al. Vitamin C and E supplementation hampers cellular adaptation to endurance training in humans: a double-blind, randomised, controlled trial. J Physiol. 2014;592(8):1887-1901. PMID: 24492839
9. Roberts LA, Raastad T, Markworth JF, et al. Post-exercise cold water immersion attenuates acute anabolic signalling and long-term adaptations in muscle to strength training. J Physiol. 2015;593(18):4285-4301. PMID: 26174323
10. Schwedhelm E, Maas R, Freese R, et al. Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism. Br J Clin Pharmacol. 2008;65(1):51-59. PMID: 17662090
11. Yang Y, Lu X, Liu N, et al. Metformin decelerates aging clock in male monkeys. Cell. 2024;187(22):6358-6378. PMID: 39270656 · doi:10.1016/j.cell.2024.08.021
12. Vinicki M, Pribić T, Vučković F, et al. Effects of testosterone and metformin on the GlycanAge index of biological age and the composition of the IgG glycome. GeroScience. 2025;47(2):1777-1788. PMID: 39363095 · doi:10.1007/s11357-024-01349-z